Kento Maeda

Kento Maeda

Auto-generated profile, based on publicly available information

Kento Maeda

Department of Glyco-Oncology and Medical Biochemistry, Osaka International Cancer Institute, Osaka, Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Molecular Aspects of Medicine
Verified
Journal Article
Closed access
Naoyuki TaniguchiNaoyuki Taniguchi
Naoyuki Taniguchi
YOYuki Ohkawa
Yuki Ohkawa
KMKento Maeda
Kento Maeda
YHYoichiro Harada
Yoichiro Harada
MNMasamichi Nagae
Masamichi Nagae
YIYoshitaka Ikeda
Yoshitaka Ikeda

7 September 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
YHYoichiro Harada
Yoichiro Harada
YOYuki Ohkawa
Yuki Ohkawa
KMKento Maeda
Kento Maeda
NTNaoyuki Taniguchi
Naoyuki Taniguchi
The endoplasmic reticulum (ER) is equipped with multiple quality control systems (QCS) that are necessary for shaping the glycoproteome of eukaryotic cells. These systems facilitate the productive folding of glycoproteins, eliminate defective products, and function as effectors to evoke cellular signaling in response to various cellular stresses. These ER functions largely depend on glycans, which contain sugar‐based codes that, when needed, function to recruit carbohydrate‐binding proteins that determine the fate of glycoproteins. To ensure their functionality, the biosynthesis of such glycans is therefore strictly monitored by a system that selectively degrades structurally defective glycans before adding them to proteins. This system, which is referred to as the glycan QCS, serves as a mechanism to reduce the risk of abnormal glycosylation under conditions where glycan biosynthesis is genetically or metabolically stalled. On the other hand, glycan QCS increases the risk of global hypoglycosylation by limiting glycan availability, which can lead to protein misfolding and the activation of unfolded protein response to maintaining cell viability or to initiate cell death programs. This review summarizes the current state of our knowledge of the mechanisms underlying glycan QCS in mammals and its physiological and pathological roles in embryogenesis, tumor progression, and congenital disorders associated with abnormal glycosylation.

10 September 2022 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
Naoyuki TaniguchiNaoyuki Taniguchi
Naoyuki Taniguchi
YOYuki Ohkawa
Yuki Ohkawa
KMKento Maeda
Kento Maeda
NKNoriko Kanto
Noriko Kanto
EJEmma Lee Johnson
Emma Lee Johnson
YHYoichiro Harada
Yoichiro Harada

20 October 2023 in Journal of Biological Chemistry
Verified
Journal Article
Open access
NKNoriko Kanto
Noriko Kanto
YOYuki Ohkawa
Yuki Ohkawa
MKMasato Kitano
Masato Kitano
KMKento Maeda
Kento Maeda
MSMasafumi Shiida
Masafumi Shiida
Naoyuki TaniguchiNaoyuki Taniguchi
Naoyuki Taniguchi
Glycan structure is often modulated in disease or predisease states, suggesting that such changes might serve as biomarkers. Here, we generated a monoclonal antibody (mAb) against the core fucose of the N-glycan in human IgG. Notably, this mAb can be used in Western blotting and ELISA. ELISA using this mAb revealed a low level of the core fucose of the N-glycan in IgG, suggesting that the level of acore fucosylated (noncore fucosylated) IgG was increased in the sera of the patients with lung cancer, chronic obstructive pulmonary disease, and interstitial pneumonia compared to healthy subjects. In a coculture analysis using human lung adenocarcinoma A549 cells and antibody-secreting B cells, the downregulation of the FUT8 (α1,6 fucosyltransferase) gene and a low level of core fucose of the N-glycan in IgG in antibody-secreting B cells were observed after coculture. A dramatic alteration in gene expression profiles for cytokines, chemokines, and their receptors were also observed after coculturing, and we found that the identified C-C motif chemokine 2 was partially involved in the downregulation of the FUT8 gene and the low level of core fucose of the N-glycan in IgG in antibody-secreting B cells. We also developed a latex turbidimetric immunoassay using this mAb. These results suggest that communication with C-C motif chemokine 2 between lung cells and antibody-secreting B cells downregulate the level of core fucose of the N-glycan in IgG, i.e., the increased level of acore fucosylated (noncore fucosylated) IgG, which would be a novel biomarker for the diagnosis of patients with pulmonary diseases.

25 May 2023 in Antioxidants & Redox Signaling
Verified
Journal Article
Closed access
YOYuki Ohkawa
Yuki Ohkawa
MKMasato Kitano
Masato Kitano
KMKento Maeda
Kento Maeda
MNMiyako Nakano
Miyako Nakano
NKNoriko Kanto
Noriko Kanto
NTNaoyuki Taniguchi
Naoyuki Taniguchi
Aims: The anticancer function of superoxide dismutases (SODs) is still controversial. SOD3 is an extracellular superoxide dismutase and contains a single N -glycan chain. The role played by the N -glycosylation of SOD3, as it relates to lung cancer, is poorly understood. For this, we performed the structural and functional analyses of the N -glycan of SOD3 in lung cancer. Results: We report herein that the fucose structure of the N -glycan in SOD3 was increased in the sera of patients with lung cancer. In cell lines of non-small lung cancer cell (NSCLC), we also found a high level of the core fucose structure in the N -glycan of SOD3, as determined by lectin blotting and mass spectrometry analysis. To address the roles of the core fucose structure of SOD3, we generated FUT8 (α1,6-fucosyltransferase) gene knockout A549 cells. Using these cells, we found that the core fucose structure of SOD3 was required for its secretion and enzymatic activity, which contributes to the suppression of cell growth of NSCLC cells. Innovation: The core fucosylation is required for the secretion and enzymatic activity of SOD3, which contributes to anti-tumor functions such as the suppression of cell growth of NSCLC. Conclusion: The N -glycans, especially those with core fucose structures, regulate the anti-tumor functions of SOD3 against NSCLC. Antioxid. Redox Signal . 38, 1201–1211.

21 January 2020 in The Journal of Biochemistry
Verified
Journal Article
Closed access
KMKento Maeda
Kento Maeda
MTMasayoshi Tasaki
Masayoshi Tasaki
YAYukio Ando
Yukio Ando
KOKazuaki Ohtsubo
Kazuaki Ohtsubo
Maintenance of cell surface residency and function of glycoproteins by lectins are essential for regulating cellular functions. Galectins are β-galactoside-binding lectins and form a galectin-lattice, which regulates stability, clustering, membrane sub-domain localization and endocytosis of plasmalemmal glycoproteins. We have previously reported that galectin-2 (Gal-2) forms a complex with cationic amino acid transporter 3 (CAT3) in pancreatic β cells, although the biological significance of the molecular interaction between Gal-2 and CAT3 has not been elucidated. In this study, we demonstrated that the structure of N-glycan of CAT3 was either tetra- or tri-antennary branch structure carrying β-galactosides, which works as galectin-ligands. Indeed, CAT3 bound to Gal-2 using β-galactoside epitope. Moreover, the disruption of the glycan-mediated bindings between galectins and CAT3 significantly reduced cell surface expression levels of CAT3. The reduced cell surface residency of CAT3 attenuated the cellular arginine uptake activities and subsequently reduced nitric oxide production, and thus impaired the arginine-stimulated insulin secretion of pancreatic β cells. These results indicate that galectin-lattice stabilizes CAT3 by preventing endocytosis to sustain the arginine-stimulated insulin secretion of pancreatic β cells. This provides a novel cell biological insight into the endocrinological mechanism of nutrition metabolism and homeostasis.